Quantifying the treatment effect explained by markers in the presence of measurement error

Statistics in Medicine

Volumn 26, Issue 9, 2007, Pages 1955-1963

  Sarkar, Somnath ^a   Qu, Yongming ^b  

^a GENENTECH INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Excess relative odds; Measurement error; Regression calibration; Surrogate marker

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; RALOXIFENE;

ACCURACY; ANALYTICAL ERROR; ARTICLE; BONE DENSITY; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMUR NECK; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MEASUREMENT ERROR; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT MONITORING; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SPINE RADIOGRAPHY; TREATMENT RESPONSE; VERTEBRA FRACTURE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DENSITOMETRY, X-RAY; FRACTURES, BONE; HUMANS; LOGISTIC MODELS; OSTEOPOROSIS; RALOXIFENE; TREATMENT OUTCOME;

EID: 34047205026     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2695     Document Type: Article

References (29)

1. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In Clinical Measurement in Drug Evaluation, Nimmo WS, Tucker GT (eds). Wiley: New York, 1995.
2. Prentice RL. Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 1989; 8:431-440.
3. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11:167-178.
4. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in Medicine 2001; 20:3175-3188.
5. Chen C, Wang H, Snapinn SM. Proportion of treatment effect (PTE) explained by a surrogate marker. Statistics in Medicine 2003; 22:4349-4359.
6. Qu Y, Case M. Quantifying the indirect treatment effect via surrogate markers. Statistics in Medicine 2006; 25:223-231.
7. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. The American Journal of Medicine 2002; 112:281-289.
8. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. Journal of Clinical Densitometry 2004; 7:255-261.
9. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. Journal of Bone and Mineral Research 2002; 17:1-10.
10. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. Journal of Bone and Mineral Research 2004; 19:394-401.
11. Reginster JY, Minne HW, Sorensen OH et al. Osteoporosis International 2000; 11:83-91.
12. Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? Journal of Clinical Densitometry 2002; 5:s29-s38.
13. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 1997; 337:1641-1647.
14. Qu Y, Kulkarni PM, Sanger TM. Estimating the response rate in the presence of measurement error. Statistics in Medicine, in press.
15. Marcus R, Wong M, Heath H, Stock J. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Reviews 2002; 23:16-37.
16. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for measurement error: the case of multiple covariates measured with error. American Journal of Epidemiology 1990; 132:734-745.
17. Carroll RJ, Stefanski LA. Approximate quasilikelihood estimation in models with surrogate predictors. Journal of the American Statistical Association 1990; 85:652-663.
18. Fuller WA. Measurement Error Models. Wiley: New York, 1987.
19. Carroll RJ, Ruppert D, Stefanski LA, Craineceanu CM. Measurement Error in Nonlinear Models: A Modern Perspective (2nd edn). Chapman & Hall, CRC Press: London, Boca Raton, FL, 2006.
20. Thoresen M, Laake P. A simulation study of measurement error correction methods in logistic regression. Biometrics 2000; 56:868-872.
21. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Journal of the American Medical Association 1999; 282:637-645.
22. Landin R, Freedman LS, Carroll RJ. Adjusting for time trends when estimating the relationship between dietary intake obtained from a food frequency questionnaire and true average intake. Biometrics 1995; 51:169-181.
23. Cook J, Stefanski LA. A simulation extrapolation method for parametric measurement error models. Journal of the American Statistical Association 1994; 89:1314-1328.
24. Novick SJ, Novick, Stefanski LA. Corrected score estimation via complex variable simulation extrapolation. Journal of American Statistical Association 2002; 97:472-481.
25. Huang Y, Wang CY. Cox regression with accurate covariate unascertainable: a nonparametric correction approach. Journal of the American Statistical Association 2000; 95:1209-1219.
26. Hu C, Lin DY. Cox regression with covariate measurement error. Scandinavian Journal of Statistics 2002; 29:637-656.
27. Chen C, Snapinn S. Separate modeling approaches for survival analysis with inaccurate covariate measurements. Journal of Biopharmaceutical Statistics 2004; 14:375-387.
28. Gorfine M, Hsu L, Prentice RL. Nonparametric correction for covariate measurement error in a stratified Cox model. Biostatistics 2004; 5:75-87.
29. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125:605-613.